Display Settings:

Format

Send to:

Choose Destination

    AIDS. 2008 Aug 20;22(13):1673-5.

    First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America.

    Young B, Squires K, Patel P, Dejesus E, Bellos N, Berger D, Sutherland-Phillips DH, Liao Q, Shaefer M, Wannamaker P.

    Division of General Internal Medicine, University of Colorado, Rose Medical Center, Denver, Colorado 80220, USA. byoung@didc.us

    A hypersensitivity reaction is associated with abacavir in approximately 2-8% of exposed patients. The frequency of the HLA-B*5701 allele varies across racial groups and significantly correlates with risk of hypersensitivity. Studies in Europe and Western Australia demonstrated that prospective screening can significantly reduce the rate of hypersensitivity by avoiding the use of abacavir in patients carrying the HLA-B*5701 allele. Prospective HLA-B*5701 screening in a large, racially diverse North American population resulted in less than 1% of individuals diagnosed with a suspected abacavir hypersensitivity reaction (ABC HSR) and no positive skin patch test through 30 weeks among HLA-B*5701-negative individuals.

    PMID: 18670229 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Patient drug information

    Recent activity

    Your browsing activity is temporarily unavailable.

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    » See more...